Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Status:Active, not recruiting
Conditions:Breast Cancer, Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:September 2012
End Date:December 2019

Use our guide to learn which trials are right for you!

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of
an investigational combination of drugs. Phase I studies also try to define the appropriate
dose of the investigational combination to use for further studies. "Investigational" means
that the combination of these drugs is still being studied and that research doctors are
trying to find out more about it. It also means that the FDA has not approved either of these
drugs nor the combination of being tested for use in patients, including people with your
type of cancer.

BKM120, BYL719 and olaparib are drugs that may stop cancer cells from growing abnormally.
These drugs when combined in laboratory experiments with animals, have demonstrated
anti-cancer activity. Information from these other research studies suggests that the
following agents BKM120, BYL719 and olaparib, may help to shrink tumor cells in the types of
cancers being studied in this research study.

In this research study, the investigators are looking for the highest dose that can be given
safely and also to see if the combination of BKM120 or BYL719 and olaparib is effective in
treating your type of cancer.

During this study, additional tests will be performed on a sample of your original tumor that
has been stored in your institutions tissue banks. These tests will be performed on tumor
tissue samples from previous biopsies or surgeries for your cancer. The research done on
these samples will involve looking at DNA and proteins in your cancer to see if researchers
can learn more about your type of cancer and understand how this combination of drugs might
work on your tumor. Testing of this sample will not require you to undergo any additional
research procedures.

Approximately 2 tablespoons of blood will be collected for research testing. This testing
will involve looking at DNA and proteins in your blood to compare them with those seen in
your cancer. This will be drawn before you begin taking the study drug.

You may also participate in an optional blood test for the BRCA gene. The BRCA gene test is a
blood test that uses DNA analysis to see changes in either one of two breast cancer genes,
known as BRCA1 or BRCA2. After having a BRCA gene test performed, you learn whether you carry
an inherited BRCA gene mutation. If your blood is tested for the BRCA gene, the results will
be reported to your study doctor who will share the results with you and provide information
related to your personal risk of breast cancer. Having a BRCA gene mutation is rare,
occurring in only about 1 in 1000 people. Inherited BRCA gene mutations are responsible for
less than 5 to 10 percent of breast cancers and about 10 to 15 percent of ovarian cancers.

Participants in the dose expansion portion of the study may be asked to have a tumor biopsy
done. The dose expansion phase for the combination of BKM120 and Olaparib has been
determined. The combination of BYL719 and Olaparib is currently in the dose escalation phase
and the dose expansion phase has not been determined. Before and after you begin taking
BKM120 (or BYL719) and olaparib, your doctor may also ask you to participate in an optional
study where you would have tumor biopsies done.

Participation in the tumor biopsy and blood test for the BRCA gene are optional, and whether
you consent or refuse to undergo these additional tests will not affect your participation in
the main research study.

Since the investigators are looking for the highest dose of the study drug that can be
administered safely without severe or unmanageable side effects in participants that have
high grade serious ovarian cancer or triple negative breast cancer, not everyone who
participates in this research study will receive the same dose of the study drug. The dose
you get will depend on the number of participants who have been enrolled in the study before
you and how well they have tolerated their doses.

All drugs are in oral form. If you take part in this research study, you will be given a
study dosing calendar for each drug for each treatment cycle. Each treatment cycle lasts 4
weeks. BKM120 or BYL719 should be taken once daily in the morning, one hour after a light
meal. Olaparib should be taken twice a day continuously, about twelve hours apart. The
olaparib morning dose should be taken at the same time as BKM120 or BYL719 one hour after a
light meal. The evening dose can also be taken one hour after a light meal or on an empty
stomach either 1 hour before or 2 hours after meals. If you vomit either or both medications,
record this on your diary and do not take another dose that day.

The investigators will assess your tumor by CT or MRI scan every 8 weeks. During Cycle 1, you
will come into the clinic every week, and during cycle 2, you will come into clinic every 2
weeks. For all cycles thereafter, you will come in once every 4 weeks.

During study visits you will undergo some or all of the following: evaluation of performance
status, recording of any healthy problems, physical exam including vital signs, list of
medications taken since last visit, questionnaire to evaluate anxiety and depression, routine
blood tests, research blood tests, Electrocardiogram and optional biopsy.

You will remain in this research study as long as you are benefitting from study treatment.
If you are removed from the research study for any reason you may be followed for up to one

Inclusion Criteria:

- Histologically or cytologically confirmed recurrent high grade serous ovarian cancer
or triple negative breast cancer

- Subjects with recurrent, metastatic triple negative breast cancer must have had at
least 1 chemotherapy regimen for metastatic breast cancer or have developed metastatic
breast cancer within 1 year of completion of adjuvant chemotherapy

- Prior therapy for high grade serous ovarian cancer subjects must have included a
first-line platinum-based regimen

- At least 4 weeks since prior radiation therapy, 3 weeks since prior chemotherapy and 6
weeks if the last regimen included BCNU or mitomycin C

- At least 4 weeks since any small-molecular kinase inhibitors or any other type of
investigational agent

- Life expectancy of at least 4 months

- Able to swallow and tolerate oral medications

Exclusion Criteria:

- Evidence of bowel obstruction, abdominal fistula, gastrointestinal perforation or
intra-abdominal abscess within 6 months of study entry

- Current dependency on IV hydration or total parental nutrition

- Diabetes mellitus unless well controlled

- Pregnant or breast feeding

- History of grade 3 or 4 toxicities with previous PI3kinase inhibitor or PARP inhibitor

- Current or active dermatologic diagnoses that would preclude interpretation of skin
toxicities of BKM120

- Receiving any medications or substances that are strong inhibitors or inducers of

- History of cardiac dysfunction or disease

- Persistent toxicities (greater than or equal to CTCAE grade 2) caused by previous
cancer therapy

- Major surgery within 14 days of starting study treatment

- Evidence of coagulopathy or bleeding diathesis

- History of major depressive episode, bipolar disorder, obsessive/compulsive disorder,
schizophrenia, history of suicide attempt or ideation or homicide/homicidal ideation

- CTCAE grade 3 or greater anxiety

- Uncontrolled, intercurrent illness

- Known HIV positive and on combination antiretroviral therapy

- Receiving chronic treatment with steroids or another immunosuppressive agent
We found this trial at
330 Brookline Ave
Boston, Massachusetts 02215
Principal Investigator: Gerburg Wulf, MD
Phone: 617-667-1940
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Boston, MA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
Principal Investigator: Michael Birrer, MD, PhD
Phone: 617-643-5150
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Principal Investigator: Ursula Matulonis, MD
Phone: 617-582-7738
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Boston, MA
Click here to add this to my saved trials
Houston, Texas 77030
Houston, TX
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
New York, NY
Click here to add this to my saved trials